Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
Charles M RudinHardev S PandhaMatthew ZibelmanWallace L AkerleyKevin J HarringtonDaphne DayAndrew G HillSteven J O'DayTimothy D ClayGavin M WrightRoss R JennensDavid E GerberJonathan E RosenbergChristy RalphDavid C CampbellBrendan D CurtiJaime R MerchanYixin RenEmmett V SchmidtLisa GuttmanSumati V GuptaPublished in: Journal for immunotherapy of cancer (2023)
NCT02043665.